Fed. Circ. Won't Rethink Ruling Invalidating 2 Vimovo Patents
The full Federal Circuit said Tuesday it would not reconsider a May ruling that invalidated two patents on Horizon Pharma's pain reliever Vimovo, leaving in place a decision the drugmaker argued...To view the full article, register now.
Already a subscriber? Click here to view full article